IL151017A0 - Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor - Google Patents

Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Info

Publication number
IL151017A0
IL151017A0 IL15101701A IL15101701A IL151017A0 IL 151017 A0 IL151017 A0 IL 151017A0 IL 15101701 A IL15101701 A IL 15101701A IL 15101701 A IL15101701 A IL 15101701A IL 151017 A0 IL151017 A0 IL 151017A0
Authority
IL
Israel
Prior art keywords
adrenoceptor
alpha
prevention
treatment
compounds useful
Prior art date
Application number
IL15101701A
Other languages
English (en)
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of IL151017A0 publication Critical patent/IL151017A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL15101701A 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor IL151017A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
IL151017A0 true IL151017A0 (en) 2003-02-12

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15101701A IL151017A0 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Country Status (22)

Country Link
EP (1) EP1253926A1 (ru)
JP (1) JP2003522148A (ru)
KR (1) KR20020080413A (ru)
AU (1) AU780802B2 (ru)
BR (1) BR0108221A (ru)
CA (1) CA2399421A1 (ru)
CZ (1) CZ20022884A3 (ru)
EA (1) EA200200846A1 (ru)
EE (1) EE200200435A (ru)
GE (1) GEP20043356B (ru)
HR (1) HRP20020746A2 (ru)
HU (1) HUP0300032A3 (ru)
IL (1) IL151017A0 (ru)
IS (1) IS6476A (ru)
MX (1) MXPA02007454A (ru)
MY (1) MY133957A (ru)
NO (1) NO20023773D0 (ru)
NZ (1) NZ520500A (ru)
PL (1) PL357872A1 (ru)
SK (1) SK11472002A3 (ru)
WO (1) WO2001058454A1 (ru)
YU (1) YU59102A (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000615A (es) * 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
AU780802B2 (en) 2005-04-21
EE200200435A (et) 2003-12-15
HUP0300032A2 (en) 2003-05-28
EA200200846A1 (ru) 2002-12-26
CZ20022884A3 (cs) 2003-02-12
WO2001058454A1 (en) 2001-08-16
GEP20043356B (en) 2004-04-13
EP1253926A1 (en) 2002-11-06
HRP20020746A2 (en) 2004-12-31
BR0108221A (pt) 2003-03-05
HUP0300032A3 (en) 2006-01-30
AU3551001A (en) 2001-08-20
KR20020080413A (ko) 2002-10-23
NZ520500A (en) 2005-01-28
MY133957A (en) 2007-11-30
JP2003522148A (ja) 2003-07-22
YU59102A (sh) 2005-11-28
CA2399421A1 (en) 2001-08-16
SK11472002A3 (sk) 2003-02-04
NO20023773L (no) 2002-08-09
PL357872A1 (en) 2004-07-26
NO20023773D0 (no) 2002-08-09
MXPA02007454A (es) 2004-08-23
IS6476A (is) 2002-07-19

Similar Documents

Publication Publication Date Title
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL144101A0 (en) Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin d2
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
EP1274444A4 (en) DRUGS FOR THE TREATMENT OF PSYCHIATRICAL OR ABUSUS-RELATED DISORDER
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
GB0028583D0 (en) Therapeutic compounds
ZA200403568B (en) Treatment of a wide range of titanium compounds.
EP1461030A4 (en) AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
AU8339301A (en) Compounds for the treatment of addictive disorders
HRP20020746A2 (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
IL159511A0 (en) Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
AU2002350895A1 (en) Disease treatment using two related compounds wherein at least one of the compound induces a tachyphylactic response which not affect the other compound
AU2000272704A1 (en) Use of compounds for the treatment of obesity
GB0013105D0 (en) Therapeutic compounds
AU2002359282A1 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
HU0004057D0 (en) Process for the treatment of solid refuse
GB0020093D0 (en) A composition for the treatment of pruritus
GB0023982D0 (en) Therapeutic Compounds